113
0 Kommentare
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050 - Seite 3
About BostonGene Corporation
BostonGene has a mission to provide transformative, AI-integrated molecular analytics and biomarker discovery for precision matching of therapies to improve the lives of patients living with cancer
and other immune-related diseases. BostonGene’s service model provides customized client solutions using a multi-omic approach prioritized for real-world impact, including optimized
standard-of-care therapies, accelerated research and cost-effective, measurable results. BostonGene’s tests reveal key drivers of each patient’s unique disease profile, including an in-depth
profile of the immune microenvironment, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests
generate a personalized roadmap for therapeutic decision-making for each patient. For more information, visit BostonGene at http://www.BostonGene.com.
Contacts:
Transgene
Lucie Larguier VP, Corporate Communications & IR +33 (0)3 88 27 91 04 investorrelations@transgene.fr |
Media: MEDiSTRAVA Consulting Frazer Hall/Sylvie Berrebi +44 (0)203 928 6900 transgene@medistrava.com |
NEC
Joseph Jasper
+81-3-3798-6511
j-jasper@nec.com
BostonGene
Erin O’Reilly
+1-617-283-2285
Erin.Oreilly@BostonGene.com
Lesen Sie auch
Transgene disclaimer
This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The
occurrence of any of these risks could have a significant negative outcome for the Company’s activities, perspectives, financial situation, results, regulatory authorities’ agreement with
development phases, and development. The Company’s ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of
human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by
government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company’s actual results, financial condition, performance or achievements to differ from those
contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Universal Registration Document, available on the AMF website
(http://www.amf-france.org) or on Transgene’s website (www.transgene.fr). Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to
update these forward-looking statements, even if new information becomes available in the future.